IN THE CLAIMS:

Under 37 C.F.R. § 1.121(c), please amend the claims as follows:

1.-2. (Previously Canceled)

3. (Currently Amended) A pharmaceutical composition ~~for the treatment of injured mammalian nerve tissue,~~ comprising a compound in an amount effective for the treatment of injured mammalian nerve tissue and a pharmaceutically acceptable carrier, ~~and an effective amount of a~~ said compound according to the formula:



or a pharmaceutically acceptable salt or solvate thereof, wherein:

R^1 is H or a C_1-C_4 alkyl group;

R^2 is a  group, a  group or an OR group;

R^3 is H, a C_1-C_{20} alkyl group, an OR group, an alkylene ester group  , or an amine group $-NR^{11}R^{12}$;

R^4 and R^5 are aryl or aryloxy;

R is a C_1-C_{20} alkyl group, an aryl group or an alkylene aryl group;

R^{10} is a C_1-C_{10} alkyl group, and n is 1 to 20;

R^{11} and R^{12} are each independently selected from the group consisting of H, C_1-C_4 alkyl, aryl, alkylene aryl and an alkylene ester group, providing that at least one of R^{11} or R^{12} is H;

R^6 is H, C_1-C_4 alkyl, F, Cl, Br, I, NO_2 or a $NR^{13}R^{14}$ group, where R^{13} and R^{14} are each independently H or a C_1-C_3 alkyl group; or

R^3 and R^6 are taken together to form a $-(CH_2)_m-$ group, where m is 1-3; or

R^{12} and R^6 are taken together to form a $-(CH_2)_z-$ group where z is 0 to 2; or

R^3 and R^{14} are taken together to form a $-(CH_2)_p-$ group where p is 0 to 3; and

each of R^7, R^8, and R^9 is independently selected from the group consisting of H, C_1-C_4 alkyl, F, Cl, Br, I and NO_2.

~~or a pharmaceutically acceptable salt thereof, wherein R^1 is H or a C_1-C_4 alkyl group;~~

~~R^2 is a~~  ~~group, a~~  ~~group or an OR group; wherein R^3 is H, a C_1-C_{20} alkyl group, an OR group, an alkylene ester group~~  ~~, an amine group $NR^{11}R^{12}$; or R^3 and R^6 are taken together to form a $(CH_2)_m$ group where m is 1-3, R is a C_1-C_{20} alkyl group, an aryl group or an alkylene aryl group, R^{10} is a C_1-C_{10} alkyl group, n is 1 to 20, R^{11} is selected from the group consisting of H, C_1-C_4 alkyl, aryl, alkylene aryl and an alkylene ester group, and R^{12} is selected from the group consisting of H, C_1-C_4 alkyl, aryl, alkylene aryl and an alkylene ester group; or R^{12} and R^6 are taken together to form a $(CH_2)_z$ group where z is 0 to 2, and wherein at least one of R^{11} or R^{12} is H; R^6 is H, C_1-C_4 alkyl, F, Cl, Br, I, NO_2 or a $NR^{13}R^{14}$ group where R^{13} and R^{14} are H or a C_1-C_3 alkyl group; or R^{14} is taken together with R^3 to form a $(CH_2)_p$ group where p is 0 to 3 ; R^4 and R^5 are aryl or aryloxy; and each of R^7, R^8 and R^9 is independently selected from H, C_1-C_4 alkyl, F, Cl, Br, I and NO_2.~~

4. (Currently Amended) The pharmaceutical composition of claim 3, wherein the compound, or pharmaceutically acceptable salt or solvate thereof, is selected from the group consisting of:

N-(4-Pyridyl) *t*-Butyl Carbamate;

N-(4-Pyridyl) Ethyl Carbamate;

N-(4-Pyridyl) Methyl Carbamate;

N-(4-Pyridyl) Isopropyl Carbamate;

N-(4-Pyridyl) Dodecyl Carbamate;

N-(4-Pyridyl) Benzyl Carbamate;

N-(4-Pyridyl) Benzamide;

N-(4-Pyridyl) Acetamide;

N-(4-Pyridyl) Propionamide;

N-(4-Pyridyl) Trimethylacetamide;

N-(4-Pyridyl) Ethyl Succinamate;

N, N'-(4-Pyridyl) Urea;

N, N'-(3,4-Pyridyl) Urea;

P, P-Diphenyl N-(4-Pyridyl) Phosphinamide; and

4-Pyridinyl Phosphoramidic acid, Diphenyl Ester.~~;~~

~~and pharmaceutically acceptable salts thereof.~~

5.-17. (Previously Canceled)

18. (New) A method of treating a mammal suffering from injured mammalian nerve tissue, the method comprising the step of administering to the mammal in need thereof a pharmaceutical composition according to claim 3.

19. (New) The method of claim 18, wherein the mammalian nerve tissue was injured as a result of trauma, disease, traumatically-induced compression, tumors, hemorrhage, infectious processes, spinal stenosis, or impaired blood supply.

20. (New) The method of claim 19, wherein administration of the pharmaceutical composition restores action potential or nerve impulse conduction through a mammalian nerve tissue lesion.

21. (New) The method of claim 18, wherein the injured mammalian nerve tissue is CNS or PNS tissue.

22. (New) The method of claim 21, wherein the injured mammalian nerve tissue is spinal cord tissue and the mammal is a human.

23. (New) The method of claim 18, wherein the pharmaceutical composition includes a compound, or pharmaceutically acceptable salt or solvate thereof, selected from the group consisting of:

N-(4-Pyridyl) *t*-Butyl Carbamate;

N-(4-Pyridyl) Ethyl Carbamate;

N-(4-Pyridyl) Methyl Carbamate;

N-(4-Pyridyl) Isopropyl Carbamate;

N-(4-Pyridyl) Dodecyl Carbamate;

N-(4-Pyridyl) Benzyl Carbamate;

N-(4-Pyridyl) Benzamide;

N-(4-Pyridyl) Acetamide;

N-(4-Pyridyl) Propionamide;

N-(4-Pyridyl) Trimethylacetamide;

N-(4-Pyridyl) Ethyl Succinamate;

N, N'-(4-Pyridyl) Urea;

N, N'-(3,4-Pyridyl) Urea;

P, P-Diphenyl N-(4-Pyridyl) Phosphinamide; and

4-Pyridinyl Phosphoramidic acid, Diphenyl Ester.

24. (New) The method of claim 18, wherein the compound, or pharmaceutically acceptable salt or solvate thereof, in the pharmaceutical composition functions as a neurotrophic factor.

25. (New) The method of claim 18, wherein the pharmaceutical composition is administered with another pharmaceutically active agent.

26. (New) The method of claim 25, wherein the other pharmaceutically active agent is a neurotrophic factor.

27. (New) The method of claim 18, wherein the pharmaceutical composition includes a compound, or pharmaceutically acceptable salt or solvate thereof, selected from the group consisting of: *N*-(4-Pyridyl) *t*-Butyl Carbamate; *N*-(4-Pyridyl) Ethyl Carbamate; *N*-(4-Pyridyl) Methyl Carbamate; and *N*-(4-Pyridyl) Isopropyl Carbamate.